Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 12-D-0100 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Background:
- Gum disease is a condition in which the tissue around the tooth root becomes swollen and infected. This condition can cause tooth loss if it is not treated. Who gets gum disease and how bad it will be depends on (1) the different bacteria in the mouth and (2) how the immune system of an individual handles these bacteria. Researchers want to look at the oral bacteria and genetic immune problems of different people to learn how these affect gum disease and other conditions of the mouth.
Objectives:
- To study how immune system problems may lead to problems in the mouth, including gum disease.
Eligibility:
Design:
This is a cross sectional/natural history protocol designed to investigate the clinical,
microbiologic, and immunologic consequences of genetic immune defects in the oral cavity. The hypothesis is that genetic immune defects will lead to alterations in the local immune response and microbial colonization and ultimately predispose to susceptibility to oral infections and inflammatory conditions.
In the cross-sectional phase the following individuals will be enrolled, evaluated and screened for presence and severity of periodontitis, presence of a genetic defects and sampled for studies in oral immunity and microbiome: 1) individuals diagnosed with genetic immune defects 2) individuals with severe periodontitis of suspected genetic etiology and their family members 3) healthy volunteers. Subjects identified with a genetic immune defect and with presence of oral disease (primarily periodontitis) may enter the natural history phase of the study to be clinically followed at the National Institutes of Health (NIH) over time. This protocol aims to determine whether specific genetic immune defects will predispose to oral disease (primarily periodontitis) and to better understand consequences of immune deficiency on the oral immune response and microbiome.
Primary Objectives
Secondary Objectives
Study Population (s)
The study population will include:
Design
This is a cross-sectional/natural history study for the evaluation of clinical, immunologic, and microbiologic oral manifestations (primarily periodontitis) in patients diagnosed with genetic immune defects or those with severe periodontitis of suspected genetic etiology and healthy volunteer subjects.
Cross Sectional Phase: Three groups of subjects will be enrolled in the cross-sectional phase of the study 1) individuals diagnosed with genetic immune defects 2) individuals with severe periodontitis of suspected genetic etiology and their family members that include parents or siblings 3) healthy volunteers (with/without periodontal disease). All groups will be evaluated for oral disease (periodontitis) may be and sampled for oral immunity, systemic immunity and microbiome characterization. Individuals with severe periodontitis in the presence/absence of a genetic defect may be offered the option of receiving standard of care inflammatory control periodontal treatment at NIH without travel compensation, following the cross-sectional portion of the study. Family members (parents or siblings) of individuals with periodontal disease of suspected genetic may be asked to participate in this study. During the course of genetic testing, family members may be enrolled in the cross sectional phase of the study for phenotyping and genetic testing.
Natural History Phase: Subjects identified with a genetic defect with the presence of oral disease may enroll in the natural history phase of the study to be followed clinically over time.
Primary Outcome Measures
Secondary Outcome Measures
Exploratory Outcome Measures
Initial data from this study may generate new hypotheses for investigation as part of this study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healthy Volunteers | Healthy volunteers (with/without periodontal disease) | ||
| Immune deficient patients | Subjects with known genetic immune deficiency | ||
| Subjects with severe periodontitis of suspected genetic etiology and their family | Subjects with severe periodontitis of suspected genetic etiology and their family members |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| 3. Characterize the microbiome in the oral cavity of patients with genetic immune defects | The primary clinical endpoints of the study are severity and types of oral disease: specifically for periodontal disease, mean PD, mean CAL, proportion of sites with PD >5 mm, and proportion of subjects with BOP, proportion of patient with other inflammatory conditions or infections of the oral cavity by immune disorder.Characterization of the oral microbiome in patients with monogenic immune defects. Immunologic endpoints: types and levels of immune mediators in the saliva, GCF, oral tissues, and/or blood. | 25 years |
| 2. Characterize the immune response in the oral cavity of patients with genetic immune defects | The primary clinical endpoints of the study are severity and types of oral disease: specifically for periodontal disease, mean PD, mean CAL, proportion of sites with PD >5 mm, and proportion of subjects with BOP, proportion of patient with other inflammatory conditions or infections of the oral cavity by immune disorder.Characterization of the oral microbiome in patients with monogenic immune defects. Immunologic endpoints: types and levels of immune mediators in the saliva, GCF, oral tissues, and/or blood. | 25 years |
| 1. Clinical intraoral characterization (i.e., presence and severity of periodontitis). | The primary clinical endpoints of the study are severity and types of oral disease: specifically for periodontal disease, mean PD, mean CAL, proportion of sites with PD >5 mm, and proportion of subjects with BOP, proportion of patient with other inflammatory conditions or infections of the oral cavity by immune disorder.Characterization of the oral microbiome in patients with monogenic immune defects. Immunologic endpoints: types and levels of immune mediators in the saliva, GCF, oral tissues, and/or blood. | 25 years |
| Measure | Description | Time Frame |
|---|---|---|
| 2. Establishment of normative values for immune mediators and microbial elements at the oral cavity | Validate methodologies for measuring levels of immune mediators in oral fluids - Establish normative values of immune mediators in oral fluids and tissues - Assay development; Develop new methodologies to study pathways of the immune response in the oral cavity - Assay development: Develop new methodologies to study the microbiome in the oral cavity |
Not provided
Subjects with Genetic Immune Defects:
Patients with a known genetic immune defect will be eligible for screening inclusion under this protocol.
Diagnosed with a genetic immune defect
Willing to allow genetic testing
Subjects with Severe Periodontitis of Suspected Genetic Etiology:
History of severe periodontitis prior to age <30
Willing to allow genetic testing
->=7 years old
In good general health
Family members of Subjects with Severe Periodontitis of Suspected Genetic Etiology:
-Willing to allow genetic testing
->=7 years old
Healthy Volunteer Subjects (with/without periodontitis):
In good general health
->=18 years old
Willing to allow genetic testing
Have a minimum of 20 natural teeth
Inclusion Criteria for Natural History phase, all subjects:
Criteria for standard of care treatment:
EXCLUSION CRITERIA:
All Subjects:
Additional Exclusions for Healthy Volunteers:
Diagnosis of diabetes and/or HbA1C level >6%
More than 3 hospitalizations in the last 3years
Have an autoimmune disorder such as Lupus, Rheumatoid arthritis, etc.
In the 3 months before study enrollment, have used any of the following:
Have used tobacco products (including e-cigarettes) within 1 year of screening
Unwillingness to consent to oral biopsy
NIH employees working in the Oral Immunity and Inflammation Unit and members of the Clinical Research Core Team will not be eligible for enrollment.
Additional Exclusions for Standard of Care Treatment at NIH:
Not provided
Not provided
This is a cross sectional/natural history protocol designed to investigate the clinical, microbiologic, and immunologic consequences of genetic immune defects in the oral cavity. Three cohorts will be enrolled 1) subjects with genetic immune defects 2) subjects with severe periodontitis of suspected genetic etiology and their family members 3) healthy volunteers (with/without periodontal disease). The study involves detailed oral clinical and radiographic evaluations, standard laboratory testing and research sampling of blood and oral samples. All evaluations are performed at the NIH Clinical Center.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Laurie D Brenchley, R.D.H. | Contact | (301) 451-2551 | laurie.brenchley@nih.gov | |
| Niki M Moutsopoulos, D.D.S. | Contact | (301) 435-7182 | nmoutsop@mail.nih.gov |
| Name | Affiliation | Role |
|---|---|---|
| Niki M Moutsopoulos, D.D.S. | National Institute of Dental and Craniofacial Research (NIDCR) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Institutes of Health Clinical Center | Recruiting | Bethesda | Maryland | 20892 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 21565554 | Background | Rescigno M. The intestinal epithelial barrier in the control of homeostasis and immunity. Trends Immunol. 2011 Jun;32(6):256-64. doi: 10.1016/j.it.2011.04.003. Epub 2011 May 11. | |
| 18396104 | Background | Novak N, Haberstok J, Bieber T, Allam JP. The immune privilege of the oral mucosa. Trends Mol Med. 2008 May;14(5):191-8. doi: 10.1016/j.molmed.2008.03.001. Epub 2008 Apr 7. |
| Label | URL |
|---|---|
| NIH Clinical Center Detailed Web Page | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010510 | Periodontal Diseases |
| D010518 | Periodontitis |
| D007154 | Immune System Diseases |
| D005882 | Gingival Diseases |
| ID | Term |
|---|---|
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 25 years |
| 1. Assay development/validation for the study of tissue immunity and microbiome characterization | Validate methodologies for measuring levels of immune mediators in oral fluids - Establish normative values of immune mediators in oral fluids and tissues - Assay development; Develop new methodologies to study pathways of the immune response in the oral cavity - Assay development: Develop new methodologies to study the microbiome in the oral cavity | 25 years |
| 21169997 | Background | Maslowski KM, Mackay CR. Diet, gut microbiota and immune responses. Nat Immunol. 2011 Jan;12(1):5-9. doi: 10.1038/ni0111-5. |
| 34129837 | Derived | Williams DW, Greenwell-Wild T, Brenchley L, Dutzan N, Overmiller A, Sawaya AP, Webb S, Martin D; NIDCD/NIDCR Genomics and Computational Biology Core; Hajishengallis G, Divaris K, Morasso M, Haniffa M, Moutsopoulos NM. Human oral mucosa cell atlas reveals a stromal-neutrophil axis regulating tissue immunity. Cell. 2021 Jul 22;184(15):4090-4104.e15. doi: 10.1016/j.cell.2021.05.013. Epub 2021 Jun 14. |